Solara Active Pharma Sciences (NSE:SOLARAPP) EBIT : ₹-3,388 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Solara Active Pharma Sciences EBIT?

Solara Active Pharma Sciences's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ₹363 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹-3,388 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Solara Active Pharma Sciences's annualized ROC % for the quarter that ended in Sep. 2024 was 6.26%. Solara Active Pharma Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 9.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Solara Active Pharma Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -9.07%.

Solara Active Pharma Sciences EBIT Historical Data

The historical data trend for Solara Active Pharma Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solara Active Pharma Sciences EBIT Chart

Solara Active Pharma Sciences Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

1,825.60

3,017.40

-238.20

385.60

-3,899.00

Solara Active Pharma Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															73.80	-2,499.70	-1,425.60	174.10	362.90

Competitive Comparison of Solara Active Pharma Sciences's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solara Active Pharma Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Solara Active Pharma Sciences's EV-to-EBIT falls into.

Solara Active Pharma Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-3,388 Mil.

Solara Active Pharma Sciences (NSE:SOLARAPP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Solara Active Pharma Sciences's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	1438.8 * ( 1 - 0% )	/	( (0	+	22972.8)	/ 1 )
=	1438.8	/	22972.8
=	6.26 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22897.8	-	2812.7	-	( 180.7	-	max(0, 10483.3	-	7595.6	+	180.7	))
=	22972.8

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Solara Active Pharma Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1451.6	/	( ( (0 + max(0, 0))	+	(10991.8 + max(4357.5, 0)) )	/	1 )
=	1451.6	/	( ( 0	+	15349.3 )	/	1 )
=	1451.6	/	15349.3
=	9.46 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3838.7	+	2897.1	+	678.7)	-	(2812.7	+	0	+	244.3)
=	4357.5

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Solara Active Pharma Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-3388.3	/	37367.016
	=	-9.07 %

Solara Active Pharma Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Solara Active Pharma Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Solara Active Pharma Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Solara Active Pharma Sciences Ltd (NSE:SOLARAPP) » Definitions » EBIT

Traded in Other Exchanges

890202:India SOLARA:India 541540:India

Address

27, Vandaloor Kelambakkam Road, 2nd Floor. Admin Block, Melakottaiyur (Post), Keelakottaiyur Village, Chennai, TN, IND, 600 127

Website

https://www.solara.co.in

Solara Active Pharma Sciences Ltd is engaged in Active Pharmaceutical Ingredients manufacturer (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinod, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant and others. It also offers contract services including contract development and manufacturing, analytical services. The group has a business presence in the Asia Pacific, Europe, North America, South America, and other places, of which the majority of income is generated from the Asia Pacific countries.

Solara Active Pharma Sciences Headlines

No Headlines